3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Pancreatic Neoplasms
34
Carcinoma, Non-Small-Cell Lung
15
Breast Neoplasms
13
Neoplasm Metastasis
9
Triple Negative Breast Neoplasms
6
Neoplasms
5
Sarcoma
3
Lymphoma, Non-Hodgkin
3
Lung Neoplasms
3
Hodgkin Disease
3
Carcinoma, Squamous Cell
3
Stomach Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Small Cell Lung Carcinoma
2
Multiple Myeloma
2
Melanoma
2
Lymphoma
2
Head and Neck Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Transitional Cell
2
Carcinoma, Pancreatic Ductal
2
Carcinoma
2
Adenocarcinoma Of Esophagus
2
Adenocarcinoma
2
Urinary Bladder Neoplasms
1
Thrombocytosis
1
Thoracic Neoplasms
1
Squamous-Cell Non-Small-Cell Lung Cancer
1
Spinal Cord Compression
1
Solid Tumor
1
Interventions
pembrolizumab
1
bemarituzumab
1
Paclitaxel
1
Docetaxel
1
Carboplatin
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Squamous-Cell Non-Small-Cell Lung Cancer
×
130-nm albumin-bound paclitaxel
×
Clear all
NCT05267470
2025-03-25
FORTITUDE-201
Amgen
Phase 1
Terminated
74 enrolled
22 charts